The total settlements amount to $720 million across nine states, involving eight pharmaceutical companies, each paying different amounts over varying timeframes, with Mylan (now part of Viatris) paying approximately $284.4 million over nine years and Hikma paying about $95.8 million over one to four years.

Illinois has collected approximately $1.4 billion from nationwide opioid settlement funds, part of an estimated $50 billion total from various pharmaceutical companies, with at least $23 million allocated specifically from settlements related to deceptive practices.

Alongside Illinois, other states such as California, Colorado, New York, North Carolina, Oregon, Tennessee, Utah, and Virginia are also receiving settlement payments to address the opioid crisis.

As part of the settlement agreements, seven pharmaceutical companies are restricted from promoting opioid products and are required to monitor and report suspicious orders, while Indivior faces a ten-year ban from manufacturing or selling opioids, though it can market medications for opioid use disorder.

The opioid epidemic has had a devastating impact, with the CDC reporting around 725,000 deaths from opioid overdoses in the U.S. between 1999 and 2022, underscoring the severity of the crisis.

Illinois Attorney General Kwame Raoul emphasized the ongoing impact of opioid addiction on families and communities, highlighting the importance of holding companies accountable and securing resources for affected individuals.